From Forest to Pharma: Profiling Fungal Strains for Lovastatin Production in Cardiovascular Disease Management
Year: 2026
Type: preprint
Abstract: Background Fungal statins such as lovastatin are vital cholesterol-lowering drugs for cardiovascular disease (CVD). Novel fungal producers remain underexplored. This study screened forest soil fungi for lovastatin production and optimized culture conditions. Methods Twenty-one isolates were tested for lovastatin activity by yeast inhibition assays. Active strains underwent submerged fermentation under varying carbon sources (sucrose, maltose, lactose, mannitol, dextrose), pH (4–8), and temperature (20–40 °C). Lovastatin levels in extracts were quantified by HPLC. Top producers were identified by ITS rDNA sequencing. Results Five isolates (C1, C2, C3, D2, E1) inhibited S. cerevisiae but not C. albicans. These produced lovastatin equivalents under fermentation. The highest yield was by isolate C3 (41.6% lovastatin-equivalent) on mannitol; C1 and C2 also favored mannitol, while E1 yielded most on maltose. Low pH (4–5) abolished production; optimal output occurred at pH 6–8. No statin was made at 35–40 °C; each strain peaked at 20–30 °C. ITS sequencing identified the active isolates as Aspergillus spp. related to A. austwickii/aflatoxiformans. Conclusion Forest-derived Aspergillus strains can biosynthesize lovastatin, with yields highly dependent on culture conditions. The discovery of these lovastatin-producing fungi highlights a novel natural source for statins in CVD therapy. Further strain improvement and process optimization could enable sustainable production of fungal statins for cardiovascular health.
Source: Research Square
Authors: Shadma Siddiqui, Abdulaziz Asiri
Institution: University of Bisha
Language: English
Subfield: Applied Microbiology and Biotechnology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7235733907
